# Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer

> **NCT01511874** · PHASE4 · COMPLETED · sponsor: **HanAll BioPharma Co., Ltd.** · enrollment: 42 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** ELIGARD 22.5mg

## Key facts

- **NCT ID:** NCT01511874
- **Lead sponsor:** HanAll BioPharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2013-05
- **Final completion:** 2013-12
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2015-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01511874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01511874, "Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01511874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*